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Abstract 
Image guided technique is playing an increasingly important role in the investigation of the 
biodistribution and pharmacokinetics of drugs or drug delivery systems in various diseases, 
especially cancers. Besides anatomical imaging modalities such as computed tomography (CT), 
magnetic resonance imaging (MRI), molecular imaging strategy including optical imaging, 
positron emission tomography (PET) and single-photon emission computed tomography 
(SPECT) will facilitate the localization and quantization of radioisotope or optical probe la-
beled nanoparticle delivery systems in the category of theranostics. The quantitative meas-
urement of the bio-distribution and pharmacokinetics of theranostics in the fields of new 
drug/probe development, diagnosis and treatment process monitoring as well as tracking the 
brain-blood-barrier (BBB) breaking through by high sensitive imaging method, and the ap-
plications of the representative imaging modalities are summarized in this review. 
Key words: Image, biodistribution, pharmacokinetic, theranostics, nanoparticles, antibody. 
1. Introduction 
The properties of biodistribution and pharma-
cokinetics play a major role in influencing and deter-
mining the efficacy and safety for the treatment with a 
medicine. Currently, several image guided modalities 
have been applied in biomedicine and even in clinic, 
including magnetic resonance imaging (MRI), X-ray 
computed tomography (CT), positron emission to-
mography (PET), single-photon emission computed 
tomography (SPECT), electron microscopy, autora-
diography, optical imaging and ultrasound (US), etc. 
They are all noninvasive imaging modalities and 
proven clinical applications, and some of them are 
only extended to in-vivo research specimens as small 
as mice [1, 2]. Among them, PET and optical imaging 
are regarded as quantitative or semi-quantitative im-
aging modalities that employ radiotracers or optical 
tracers to image biodistribution of the labeled drugs 
or probe loaded delivery systems in the body, 
meanwhile CT and MRI are normally used for ana-
tomical imaging purposes [3, 4]. In these imaging 
modalities, non-invasive technique attracted more 
attention because of its properties of no breaking in 
the skin and no contact with the mucosa, internal 
body cavity beyond a natural or artificial body orifice. 
Non-invasive in vivo molecular imaging can be ob-
tained from PET, MR, CT and visible infrared in vivo 
optical imaging systems. The discovery of the first 
modern non-invasive techniques was setup at the end 
of 19th century based on physical methods: electro-
cardiography and X-rays. From that time, 
non-invasive with advantage of penetrating the body 
rather than a scalpel have continuously enlarged the 
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scope of medical technology. Non-invasive tech-
niques commonly can be used for the purpose of 
theranostics by diagnostic imaging and therapy on 
diseases [5-7].  
The ability to quantitatively image the biodis-
tribution of therapeutics or drug delivery systems in a 
noninvasive manner can aid in the development of 
new theranostic, dose optimization and treatment 
monitoring. Normally, the information of biodistri-
bution can often be obtained by dissecting the animal, 
collecting plasma or tissues and being analyzed by 
high-performance liquid chromatography (HPLC), 
Enzyme-linked immunosorbent assay (ELISA) etc 
[8-10], the key advantage of non-invasive imaging is 
less time consuming and more cost effective of ani-
mals and analysis reagents [11]. There is a critical 
need to establish an effective non-invasive tool to 
clearly diagnose diseases along with the treatment. If 
a high effective non-invasive method exists, a cancer 
patient could be more potentially received effective 
treatment at an earlier stage with concise targeted 
drug delivery [12]. 
Therefore, discussions of perspectives of various 
imaging guided modalities are focusing on the re-
search applications in biodistribution and pharmaco-
kinetics of delivery systems such as theranostics. The 
concept of the revolutionary “Theranostic” was orig-
inated by Funkhouser in 2002 from one of his reviews. 
Theranotics is defined as a material that combines the 
modalities of therapy and diagnostic imaging at the 
same time within the same dose [13]. It integrates the 
two features into one “package” to overcome unde-
sirable difference between biodistribution and thera-
peutic agents. The final goal of the theranostic is to 
donate materials with the capacity of monitoring the 
treated tissue, PK and efficacy in the long-term peri-
od. This approach will benefit nanomedicine with an 
effectively style of personalized treatment. In actual 
applciations, the combination of MRI, CT, PET, or 
optical imaging and their combination usage may add 
further impetus to the rapid and high throughput 
screening of nanoparticle delivery systems based di-
agnosis and therapeutics (Figure 1). Some representa-
tive applications of imaging modalities in the area of 
biodistribution and pharmacokinetics of nanoparti-
cles for the aim of treatment and diagnosis are also 
listed in this review.  
 
 
Figure 1. Illustration of multi-functionalized nanoparticles. Examples of multifunctional nanoparticles for (i) molecular imaging for MRI or 
PET/SPECT imaging; (ii) drug delivery, (iii) fluorescence detection with a fluorescent probe; (iv) X-ray images such as CT; (v) ultrasonic 
assistance; (vi) specific targeting, functionalized with specific ligand molecules (e.g. antibody) and (vii) drug payload.
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2. Magnetic resonance imaging (MRI) and 
computed tomography (CT) guided bio-
distribution and pharmacokinetics study 
Magnetic resonance imaging (MRI) is a 
non-invasive medical imaging to visualize detailed 
internal structures. For MR imaging, atoms in the 
body are aligned under a powerful magnetic field. 
Radio frequency fields change the alignment of the 
magnetization of atoms. This causes the nuclei to 
produce a rotating magnetic field detectable by the 
scanner, which can be recorded to construct an image 
of the body. Strong magnetic field gradients cause 
nuclei at different locations to rotate at different 
speeds, thus providing 3D spatial information. Com-
paring with other medical imaging techniques such as 
computed tomography (CT), MRI provides good 
contrast between the different soft tissues of the body, 
which make it especially useful in imaging brain, 
muscles, the heart, and cancers [14, 15]. Another ad-
vantage of MR imaging is that it does not need to use 
ionizing radiation which has damage to cell structure 
once be exposed. 
X-Rays computed tomography, also called 
computed tomography (CT scan) or computed axial 
tomography (CAT scan), can make use of radiation to 
get an internal view of the body for medical imaging 
employing tomography created by computer pro-
cessing. Although CT technique is regarded as birth 
defects or DNA altering because of powerful X-ray 
radiation exposure, it is still largely employed in hos-
pitals, especially used for broken bones and skulls. 
Not like MRI imaging which can provide subtle dif-
ferences between the different kinds of soft tissues, CT 
can demonstrate the difference between bone density 
and soft tissue. Although MRI and X-ray are both 
imaging techniques for organs of the body, the dif-
ference in application is that MRI images provide a 3D 
representation of organs, which X-Rays usually can-
not.  
Dr. Sgouros and colleagues applied MRI based 
preclinical biodistribution and localization data and 
the therapeutic potential of trastuzumab monoclonal 
antibody (mAb) (anti-HER2/neu) against ovarian 
carcinoma. By MRI images, they found out the rapid 
blood-pool uptake (5-9 hours) of mAb after intraper-
itoneal injection followed by tumor localization (26-32 
hours). And micro-PET finding was consistent with 
the data from high resolution MRI images slices for 
mAb bio-distribution in main organs of tumor-beard 
mice [16]. Dr. Teng et al conjugated anti-mouse Ox-
LDL polyclonal antibody to polyethylene gly-
col-coated ultrasmall superparamagnetic iron oxide 
(USPIO) nanoparticles, and imaged at 7.0 Tesla MRI 
on a carotid perivascular collar model in atheroscle-
rotic disease mice. The results showed MRI signal loss 
in the carotid atherosclerotic lesions after administra-
tion of targeted anti-OxLDL-USPIO at 8th hour and 
24th hour, which means that anti-mouse OxLDL an-
tibody conjugated magnetic nanoparticle can be used 
as a strategy for the therapeutic evaluation of athero-
sclerotic plaques in vivo by MRI imaging [17]. 
CT became an important tool in medical imaging 
to supplement X-rays and medical ultrasonography 
since 1970s. It has more recently been used for pre-
ventive medicine or screening for disease. CT is re-
garded as a moderate- to high-radiation diagnostic 
technique. The radiation dose for a particular study 
depends on multiple factors: volume scanned, patient 
build, number and type of scan sequences, and de-
sired resolution and image quality. Normally, the 
high resolution and image quality means the high 
exposure of radiation to patients. The high ionizing 
radiation in CT application can damage the DNA 
double strand structure in human body. In one study, 
researchers found out at a typical CT scanning, 
40%-100% of the irradiated cells is damaged by one or 
more double strand breaks in DNA molecule. Alt-
hough there is repair process in cells for damaged and 
broken DNA, the results are not satisfied [18]. That‟s 
why by now, CT technique is designed to combine 
with other image techniques for better application in 
patients. 
3. PET and SPECT image guided biodis-
tribution and pharmacokinetics study of 
theranostics  
3.1 Radiolabeling of antibody therapeutics and 
principle of PET imaging 
PET imaging is another kind of non-invasive 
option for diagnosis. Since biodistribution of anti-
body-based therapeutics is a key consideration that 
can be modulated to impact the ensuing in vivo 
pharmacological effect. After being labeled with ra-
dionuclide of sufficient long half-life, antibody ther-
apeutics can be monitored using PET (positron emis-
sion tomography) imaging with respect to pharma-
cokinetics and its biodistribution. Normally, it is as-
sumed that the labeling method does not perturb the 
property of the molecules with respect to metabolism, 
specific binding or non-specific interactions. The la-
beling isotopes include positron emitters such as 11C, 
15O, 18F, 68Ga, 64Cu, or 76Br with half-lives of 20 
minutes, 2 minutes, 2 hours, 68 minutes, 13 hours, and 
16 hours respectively. Long-lived positron emitters 
such as 89Zr and 124I with half-lives of several days, 
3.2 days for 89Zr and 4.2 days for 124I, are also available 
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[19]. Among them, Copper-64 (64Cu) is a promising 
PET radionuclide, particularly for antibody-targeted 
imaging [20]. The reported methods for modification 
include addition of labeled groups or radiolabel che-
lating groups. Compared with radio-halogenation, 
radiometal ion complexation reactions have simpler 
chemistry and allow tracer production kits. For ex-
ample, chelator 1, 4, 7, 10-tetraazacyclododecane-1, 4, 
7, 10-tetraacetic acid (DOTA) is commonly used in 
radiolabeling copper radioisotope with antibody [21].  
„MicroPET‟ is a small-animal positron emission 
tomography which uses pharmacologically or bio-
chemically active compounds labeled with short-lived 
or long-lived positron-emitting radionuclides to 
monitor their biodistribution, physiological processes 
and biochemical pathways etc [22]. These radionu-
clides are incorporated into molecules during the ra-
diosynthesis step, generating the radiotracer. PET 
scans are acquired following the injection of the radi-
otracer. The radiotracer accumulates in the tissues, 
and its radionuclide decays by emission of a positron 
(anti-electron). After travelling at most a few milli-
meters, a positron will collide with an electron, sim-
ultaneously releasing two gamma rays (photons) with 
energy of 511 keV into opposite directions. These two 
photons are detected by the PET camera and by col-
lecting a statistically significant number of radioactive 
events, mathematical algorithms reconstruct a 
three-dimensional image that shows the distribution 
of the positron-emitting molecules in the tissues [19]. 
Single-photon emission computed tomography 
(SPECT) is also one kind of nuclear medi-
cine tomographic imaging technique using gamma 
rays which can provide 3D information as PET as 
well. Normally, a marker radioisotope could be at-
tached to an nanoparticles or antibody. After being 
administered in vivo, the gamma-emission of the 
isotope from the radiolabeled materials allows the 
drug to be seen by a gamma-camera. SPECT can gen-
erate a true 3D image, which permit accurate locali-
zation of organs. Therefore, it can be used to provide 
information about localized function in internal or-
gans, such as functional cardiac or brain imaging [11]. 
3.2 PET images guided biodistribution and 
pharmacokinetic study of theranostics 
Targeted therapeutic and diagnostic nanocarri-
ers functionalized with antibodies, peptides or other 
targeting ligands that recognize over-expressed re-
ceptors or antigens on tumor cells have potential in 
the diagnosis and therapy of cancer. Biodistribution 
study of therapeutic antibodies by PET methodology 
could quantitatively measured by radiotracer in or-
gans/tissues. Biodistribution and pharmacokinetics 
could also be recorded by blood sampling at prede-
termined time points, preferably associated with ra-
diometabolite evaluation with respect to time [23]. 
PET images were used from heart to determine blood 
concentrations. Briefly, nude mice bearing human 
colon tumors (LS-174T) were injected intravenously 
with a chimeric 124I anti-CEA mAb (cT84.66) and im-
aged serially 1 hour to 7 days postinjection. The re-
sults showed that PET blood curves agreed well with 
direct measurements within 12% at all time points. 
The 4.2-day half-life of 124I favors its use for PET study 
of monoclonal antibodies (mAbs). Therefore, quanti-
tative biodistribution measurements could be 
achieved from tumor-bearing mice by using 124I an-
ti-CEA mAbs with standard microPET acquisition 
and processing techniques. Although from the ROI of 
heart on the PET images, the blood concentrations can 
be calculated, most of the case, the pharmacokinetic 
study was done by withdrawing blood sample and 
analyzing them with radioassay or ELISA [24]. 
The distribution of monoclonal antibodies is de-
termined by the rate of extravasation in tissue, the rate 
of distribution within tissue, binding affinity in tissue 
and the rates of elimination from tissue, route of in-
jection, species etc. Although PET imaging has been 
applied in the study of Integrin αVβ3 expression or 
peptide antagonist [25-27], the mAbs are large mole-
cules with MW of about 150 kDa, it seems to be very 
slow for them to diffuse across vascular endothelial 
cells. The movement of antibody into tissue by con-
vective transport is thought to be the primary mecha-
nism for the distribution in tissue [28]. The transport 
is mainly determined by the movement rate of fluid 
from blood to tissue and by the sieving effect of 
paracellular pores in the vascular endothelium. Nor-
mally, the biodistribution of drugs requires sacrificing 
a number of rodents and quantitating the tissue con-
centration by HPLC, ELISA or by counting the radio-
activity emitting from the tissue. MicroPET imaging 
provides a non-invasive way of quantitation of the 
concentration of mAbs in tissues, especially useful for 
monitoring the kinetics in target organ such as tumor. 
For instance, a chimeric anti-CD105 monoclonal 
antibody, TRC105, was conjugated to 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic 
acid (DOTA) and labeled with (64)Cu. Serial PET 
imaging revealed that the 4T1 tumor uptake of the 
tracer was 8.0 ± 0.5, 10.4 ± 2.8, and 9.7 ± 1.8%ID/g 
(percentage of injected dose per gram tissue) at 4, 24, 
and 48 h post-injection, respectively, higher than most 
organs at late time points which provided excellent 
tumor contrast. Biodistribution data as measured by 
gamma counting were consistent with the PET find-
ings [11]. Non-invasive PET imaging of vascular en-
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dothelial growth factor (VEGF) expression using ra-
diolabeled bevacizumab has been investigated in 
ovarian cancer models [29]. Small-animal PET and 
microCT images were used to calculate tumor uptake 
and compared with ex vivo biodistribution at 168 h 
after injection. The tumor accumulation of 89Zr labeled 
bevacizumab was calculated to be 7.38 %ID/g using 
small-animal PET imaging, which is equivalent to ex 
vivo biodistribution studies. Liver and spleen were 
the other organs that uptake tracer bevacizumab. This 
project demonstrated the quantization of ra-
dio-labeled bevacizumab in tumor using non-invasive 
imaging is convenient, which was also validated by ex 
vivo biodistribution studies. Since VEGF is a major 
angiogenic factor responsible for the development of 
tumor vasculature, the expression level of VEGF 
could be regarded as a factor indicating disease pro-
gress. PET imaging were performed in mice bearing 
human colorectal cancer (HT29) xenografts to inves-
tigate the in vivo biodistribution of VEGF after injec-
tion of 64Cu-DOTA-bevacizumab. The accumulation 
of 64Cu-DOTA -bevacizumab in the tumor was 22.7 
%ID/g, 24 %ID/g, 19.0 %ID/g at 24, 48 and 72 h, re-
spectively, which was significantly correlated with 
VEGF expression as measured by western blot (q = 
0.81, P = 0.004) [30].  
Currently, the PK and biodistribution were also 
conducted not only for antibodies, but also for anti-
body or peptide functionalized theranostics. For ex-
ample, Dr. Cai W etc. employed PET imaging using 
(66)Ga as the radiolabel to quantitatively evaluate the 
pharmacokinetics and tumor targeting efficacy of 
nano-graphene. Nano-graphene oxide (GO) sheets 
with covalently linked, amino group-terminated 
six-arm branched polyethylene glycol (PEG; 10 kDa) 
chains were conjugated to NOTA 
(1,4,7-triazacyclononane-1,4,7-triacetic acid, for 
(66)Ga-labeling) and TRC105 (an antibody that binds 
to CD105). TRC105-conjugated GO was specific for 
CD105 in cell culture. (66)Ga-NOTA-GO-TRC105 and 
(66)Ga-NOTA-GO exhibited excellent stability in 
complete mouse serum. In 4T1 tumor-bearing mice, 
these GO conjugates were primarily cleared through 
the hepatobiliary pathway. (66)Ga-NOTA-GO- 
TRC105 accumulated quickly in the 4T1 tumors and 
tumor uptake remained stable over time (3.8 ± 0.4, 4.5 
± 0.4, 5.8 ± 0.3, and 4.5 ± 0.4 %ID/g at 0.5, 3, 7, and 24 h 
post-injection respectively; n = 4). PET imaging suc-
cessful demonstrated the in vivo tumor targeting 
property with GO, showing them to be suitable na-
noplatforms for future biomedical research such as 
cancer theranostics [31].  
Andresen TL et al covalently attached octreotate 
(TATE) to the distal end of DSPE-PEG(2000) on 
PEGylated liposomes with an encapsulated positron 
emitter (64)Cu that can be utilized for PET imaging. 
TATE are somatostatin peptide analogs, can target 
Somatostatin receptors (SSTRs) that are 
over-expressed in neuroendocrine tumors (NETs). 
They used PET imaging to investigate the biodistri-
bution and pharmacokinetics of the (64)Cu-loaded 
PEGylated liposomes with and without TATE. They 
found that the presence of TATE on the liposomes 
resulted in a significantly faster initial blood clearance 
in comparison to control-liposomes without TATE. 
PEGylated liposomes with or without TATE accu-
mulated at significantly higher quantities in NETs 
(5.1±0.3 and 5.8±0.2 %ID/g, respectively) than the free 
peptide (64)Cu-DOTA-TATE (1.4±0.3 %ID/g) 24h 
post-injection. Importantly, (64)Cu-loaded PEGylated 
liposomes with TATE showed significantly higher 
tumor-to-muscle (T/M) ratio (12.7±1.0) than the con-
trol-liposomes without TATE (8.9±0.9) and the 
(64)Cu-DOTA-TATE free peptide (7.2±0.3). The high-
er T/M ratio of the PEGylated liposomes with TATE 
suggests some advantage of active targeting of NETs, 
although no absolute benefit in tumor accumulation 
over the non-targeted liposomes was observed. The 
results showed that (64)Cu-loaded PEGylated lipo-
somes with TATE conjugated to the surface could be 
promising new imaging agents for visualizing tumor 
tissue and especially NETs [32].  
3.3. SPECT images guided biodistribution and 
pharmacokinetics study of theranostics 
Single-photon emission computed tomography 
(SPECT) is a nuclear medicine tomographic imaging 
technique using gamma rays. Normally, a marker 
radioisotope could be attached to nanoparticles or 
antibody. After being administered in vivo, the 
gamma-emission of the isotope from the radiolabeled 
nanoparticles or antibody allows the drug to be seen 
by a gamma-camera.  
Since the source of SPECT images are gamma ray 
emissions, the radioisotope decays and emits gamma 
rays, which can be detected by a gamma camera to 
obtain 3D images, which permit accurate localization 
of organs [33]. This information is typically presented 
as cross-sectional slices through the patient, but can be 
freely reformatted or manipulated as required. 
Therefore, it can be used to provide information about 
localized function in internal organs, such as func-
tional cardiac or brain imaging. For example, 3D ac-
quisition SPECT of the liver was performed to inves-
tigate the correlation between tumor accumulation of 
In-111-bevacizumab and VEGF-A expression in pa-
tients with colorectal liver metastases [34]. 
Although heart has been used as an organ in PET 
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imaging to estimate blood concentration, for phar-
macokinetic study using SPECT imaging, the com-
monly used method is to collect blood samples from 
patients or animals at timed intervals after injection of 
the radioisotope-labeled mAb [23]. The major ad-
vantages of radionuclide-based molecular imaging 
techniques (SPECT and PET) over other modalities 
(e.g. optical and MRI) are that they are very sensitive 
(down to the picomolar level), quantitative, and there 
is no tissue penetration limit. However, one disad-
vantage is that the resolution (typically >1 mm) of 
either SPECT or PET is not as high as the other imag-
ing modalities such as MRI. In most cases, the pur-
pose of labeling the nanoparticle with a radionuclide 
was for the non-invasive evaluation of its biodistribu-
tion, pharmacokinetic properties, and/or tu-
mor-targeting efficacy with SPECT or PET [35, 
36]. Radiolabeling of nanoparticles was also applied 
for PK and biodistribution studies for the purpose of 
theranostics. Dr. Helbok et al radiolabeled 
DTPA-derivatized lipid-based nanoparticles includ-
ing including (111)In and (99m)Tc for SPECT and PET 
images with therapy in vitro and in vivo. Their study 
showed that PEGylated DTPA-nanoparticles were 
suitable for targeting applications. Biodistribution in 
Lewis rats revealed no significant differences between 
nanoparticles in terms of DTPA loading and particle 
composition; however, different uptake patterns were 
found between the radionuclides used [37]. Dr. De-
Nardo et al applied 111In-labeled, chimeric L6 (ChL6) 
monoclonal antibody linked iron oxide (IO) nanopar-
ticles for studies on pharmacokinetics, tumor uptake, 
and therapeutic efficacy in athymic mice bearing hu-
man breast cancer tumors. The 111In-labeled ChL6 
was conjugated with carboxylated polyethylene gly-
col (PEG) on dextran-coated iron oxide nanoparticles 
with one to two ChL6 antibodies per nanoparticle (Fig 
2). Inductively heating the nanoparticle by externally 
applied alternating magnetic field caused tumor ne-
crosis after 24 h of therapy. After nanoparticle injec-
tion, SPECT imaging was carried out to quantify the 
nanoparticle uptake in the tumor, which was about 14 
percentage injected dose per gram (%ID/g) at 48 h 
post-injection. A delay in tumor growth occurred after 
the alternating magnetic field treatment, which was 
statistically significant when compared with the un-
treated group [38, 39]. Dr. Misri and colleagues also 
applied SPECT imaging for mesothelin expressing in 
tumors by evaluation of 111In labeled antibodies. 
Their findings indicated that the antimesothelin an-
tibody mAbMB may be developed into a diagnostic 
agent for imaging mesothelin-expressing cancers [40]. 
Dr. Wu et al also successfully applied gamma scin-
tigraphy by pulsincap capsule in the gastrointestinal 
tract of dogs by to find out the desintegration and 
transit behavior of Tetramethylpyrazine phosphate. 
Their SPECT images confirmed the time controlled 
capsule releasing in the gastrointestinal delivery in 
dog at the expected time schedule [41].  
 
 
Figure 2. Simple radioimmuno-nanoparticles diagram of a 
BNF-type particle coated with PEG to link 111In-ChL6. The par-
ticle core has ferromagnetic property. Adapted from [39]. 
 
4. Combination of PET and SPECT with 
CT, MR or NIRF images guided biodis-
tribution and pharmacokinetic studies of 
theranostics 
Imaging modalities such as CT and PET have 
been applied sequentially in the diagnosis and staging 
of disease and in monitoring the effects of therapy for 
several years. Although PET offers high sensitivity in 
terms of molecular concentrations and it is possible to 
measure picomolar amounts of a PET radiopharma-
ceutical in a tissue. With a three dimentional images 
obtained by PET, establishing a ROI (region of inter-
est) and set the location of the organs or tissues in the 
images is of critical importance. Since accurate ana-
tomic localization of functional abnormalities seen on 
PET scans is well known to be challenging because of 
the lack of detailed, high-resolution anatomy, the fu-
sion of PET with CT in one camera unit (PET/CT) or 
fusion of PET image with MR images provides a 
merged image where not only the physiological status 
but also the anatomical details may be seen on the 
same image, which opens new ways of diagnostics 
and quantitation [42-46]. Indeed, in many cases ana-
tomic imaging is used exclusively, although func-
tional imaging with PET is fulfilling an increasingly 
Theranostics 2012, 2(11) 
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important role in the staging and therapy monitoring 
processes, particularly when the CT scan is equivocal. 
This situation changed dramatically with the recent 
introduction of the combined PET/CT scanner, an 
approach that solves the fusion problem through 
hardware rather than software. This device provides a 
medical imaging department with the capability to 
acquire accurately aligned anatomic and functional 
images for a patient from a single scanning session 
[47]. In another word, anatomical/functional imaging 
techniques help to identify the exact location of the 
signals. Since the patient remains positioned on the 
same bed for both imaging modalities, temporal and 
spatial differences between the two sets of images are 
minimized. 
Schneider DW et al used whole-body 
small-animal PET to compare the bisodistribution and 
tumor localization of 86Y or 111In-labeled antibody 
formats, derived from a single antimindin/RG-1 mAb 
in a prostate tumor model. The images were colocal-
ized with simultaneous micro-CT imaging. The anti-
body accumulation in the tumor correlated with mo-
lecular size. The larger antibody formats (IgG and 
miniantibody) gave higher tumor uptake levels than 
did the smaller formats (diabody and scFv). These 
larger formats may be more suitable for radioim-
munotherapy applications. The smaller formats were 
rapidly cleared from circulation, and the diabody, 
which accumulated in the tumor, may be more suita-
ble for radiodiagnostic applications. The combination 
of PET with CT provides easier localization of tissues 
[34, 48].  
PET is sensitive in the process of detecting and 
quantifying a low abundance molecular target in cells 
while MRI is capable of providing exquisite anatomy 
for organs. Thus, an integrated PET/MRI system will 
permit the simultaneous acquisition of several pa-
rameters in highly accurate spatial and temporal reg-
istration. Quantitative values from PET of a large 
number of biological parameters are complemented 
by the high-resolution information provided by MRI 
(in the micromolar range) to yield complementary 
information. An MRI-based method has the potential 
to improve PET image quality, increasing its reliabil-
ity, reproducibility, and quantitative accuracy [49]. 
PET data and MRI data have been combined for 
monitoring the drug anticancer effect [50], the re-
sponse of patients to antibody treatment [51] as well 
as for detection of lymph node metastases [52], which 
is very important for the improvement of tumor de-
tection and for the guide of mAb-based therapy.  
Overall, accurate quantization of PET tracer up-
take levels in tumors is important for staging and 
monitoring response to treatment. The combination 
with anatomical information obtained from CT will 
improve quantization of tumor values in terms of bias 
and variance [53]. Using appropriate software to fuse 
PET and CT image together and accurately quantify 
the tumor uptake level of tracer is of critical value. 
There is PET/CT scanner available for clinical study 
for the [54-56]. However, the integrated equipment 
which combines microPET and contrast-enhanced 
microCT for small animal study is still at the starting 
beginning stage [57, 58].  
PET and NIRF imaging was also combined to 
study the ex vivo biodistribution 
64Cu-DOTA-NuB2-Alexa Fluor 750 in CD20 positive 
Raji lymphoma-bearing mice. Raji tumor showed sig-
nificantly higher uptake of DOTA-NuB2-Alexa Fluor 
750 than that of DOTA-Alexa Fluor 750 (p<0.05). Sig-
nificant correlation was obtained between the or-
gan-to-muscle ratios measured by the radioactivity 
and fluorescence intensity [59]. In Xie's work, iron 
oxide nanoparticles with triple functional of 
PET/NIRF/MRI were applied for the in vivo biodis-
tribution study. To assess the biophysical characteris-
tics of this novel nanosystem, the HSA coated IONPs 
(HSA-IONPs) were dually labeled with 64Cu-DOTA 
and Cy5.5, and tested in a subcutaneous U87MG 
xenograft mouse model. In vivo PET/near-infrared 
fluorescence (NIRF)/MRI tri-modality imaging, 
and ex vivo analyses and histological examinations 
were carefully conducted to investigate the in vi-
vo behavior of the nanostructures. This nanosystem is 
well-suited for dual encapsulation of IONPs and drug 
molecules, with the compact HSA coating, the 
HSA-IONPs manifested a prolonged circulation 
half-life; more impressively, they showed massive 
accumulation in lesions, high extravasation rate, and 
low uptake of the particles by macrophages at the 
tumor area [60]. 
SPECT has been combined with MRI to investi-
gate the pharmacokinetics and biodistribution. For 
example, 99mTc-labeled superparamagnetic iron ox-
ide nanoparticles were employed for multimodality 
SPECT/MRI of sentinel lymph nodes. In Dr. Madru's 
work, Nanoparticles with a solid iron oxide core and a 
polyethylene glycol coating were labeled with 
(99m)Tc. Wistar rats was injected subcutaneously and 
sacrificed 4 h after injection. Animals were imaged 
with SPECT/MRI and the microdistribution within 
the lymph nodes was studied with digital autoradi-
ography. The result showed that the accumulation of 
(99m)Tc-labeled superparamagnetic iron oxide na-
noparticles (as the percentage injected dose/g 
[%ID/g]) in the lymph nodes was 100 %ID/g, 
whereas in the liver and spleen it was less than 2 
%ID/g. Digital autoradiography images revealed a 
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nonhomogeneous distribution of (99m)Tc- labeled 
superparamagnetic iron oxide nanoparticles within 
the lymph nodes; nanoparticles were found in the 
cortical, subcapsular, and medullary sinuses [61]. 
5. The optical imaging guided biodistri-
bution and pharmacokinetics study of 
theranostics 
Optical imaging is a photonic technique which 
applied in the area of imaging, describing the behav-
ior of visible, ultraviolet, and infrared light used in 
imaging [62, 63]. These optical techniques, such as 
bioluminescence and fluorescence, are emerging as 
powerful new modalities for molecular imaging in 
disease diagnosis and therapy. Optical imaging offers 
higher sensitivity and temporal resolution than PET at 
the same spatial resolution in small animals, but un-
like PET is limited to a few centimeters of tissue depth 
[35]. The bioluminescence and fluorescence can be 
obtained from dyes, specific metal materials, and bi-
ological resources etc and already used in diagnosis 
and therapy in research and clinic [64-66]. With the 
help of combing of innovative molecular biology and 
chemistry, scientists have developed optical methods 
for imaging a variety of cellular and molecular pro-
cesses in vivo, including the receptor-ligand interac-
tion, tumor targeting, bio-distribution of proteins such 
as antibody, etc. Whereas optical imaging has been 
used primarily for research in small-animal models, in 
some specific area optical imaging may have the pos-
sibility to translate into clinical medicine. The ad-
vantages of optical imaging for assessing antibody 
pharmacokinetics in vivo are the conjugation chemis-
try, cost, and high-speed throughput. The fluorophore 
conjugation chemistry is often carried out with a 
commercially available kit and can be performed in 
most laboratories without special license, equipment, 
hazardous precautions, or specific training. The de-
tection systems are generally 30 to 50% as expensive 
as those for small-animal SPECT or PET. Planar fluo-
rescence images are generated within seconds or 
minutes, typically with a photograph overlay. Optical 
imaging experiments also can accommodate four to 
five animals per scan, allowing an efficient researcher 
to perform 100+ animal images per hour, whereas 
PET and SPECT imaging is often limited to one to two 
animals per 10 to 30 min scan. Such throughput and 
cost combined with expected improvements in quan-
tification from advances in instrumentation provide 
an exciting outlook for this preclinical fluorescence 
imaging approach [67].  
A key challenge for pharmacists and clinic doc-
tors is defining the disposition of drugs such as mon-
oclonal antibody and pharmacokinetic property in 
whole animals or patients. Ongoing discoveries of 
these potential target molecules in disease also drive 
pharmaceutical and biotechnology companies to find 
leading agents that selectively regulate these molecu-
lar pathways in vitro and in vivo. Among all the ex-
isting techniques, optical imaging including biolumi-
nescence and fluorescence, are emerging as key tech-
niques to meet these challenges and advance molec-
ular imaging in preclinical research and patient care. 
Bioluminescence is the process of light emission in 
living organisms, it is a chemical process wherein 
light is emitted during the interaction of a protein 
produced in engineered cells and an administered 
substrate, for example firefly luciferase and luciferin 
[68]. Bioluminescence imaging  is a technology 
developed over the past decade that allows for the 
noninvasive study of ongo-ing biological processes in 
small laboratory animals. Bioluminescence imaging 
utilizes native light emission from one of several or-
ganisms which contain bioluminescence. Fluores-
cence is the emission of light by a substance that has 
absorbed light or other electromagnetic radiation with 
a different wavelength. It is a form of luminescence. 
Fluorescence imaging uses probes that emit light 
(fluorescence) after the excitation at a fluoro-
phore-specific wavelength. In most cases, emitted 
light has a longer wavelength, and therefore lower 
energy, than the exciting source, known as the Stokes 
shift [69]. Dr. Wu and colleagues applied NIR dye 
labeled Bevacizumab antibody to find out the phar-
macokinetics, lymph Node Uptake and mechanistic 
PK behavior model after i.v. and s.c. administration in 
mice [70, 71]; they also found an interesting phe-
nomena that after s.c. administration in mice, the 
lymph node uptake of proteins in mice had a molec-
ular weight dependence by the way of fluorescence 
imaging [72]. This finding may provide quite useful 
aim for the future protein biodistribution and phar-
macokinetic studies. 
The most important application of optical imag-
ing in the biological field is early cancer detection or 
diagnosis in preclinic and clinic studies, they pro-
vided a very useful alternative modality for tumor 
imaging [73]. Dr. Hülper P and his colleagues pub-
lished their finding of tumor localization of nti-TGF-β 
antibody and its effects on gliomas. The orthotopic 
gliomas beared mice was subcutaneous injected with 
AF680-labeled 1D11, a pan-neutralizing TGF-β anti-
body, and used for the bio-distribution study via in 
vivo imaging and fluorescence microscopy. With the 
combination of results from direct tumor size meas-
urement, H&E staining and immune-histochemistry, 
it demonstrate that TGF-β plays different roles in 
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combating the tumor depending on subcutaneous 
versus orthotopic implantation site [74]. Besides the 
monoimaging principle, combining two or more dif-
ferent imaging modalities in the same agent can be of 
considerable value in molecular imaging. By binding 
a biotinylated anti-Her2 Herceptin antibody to pro-
vide tumor targeting, a biotinylated DOTA chelator 
labeled with 111In and a biotinylated Cy5.5 fluoro-
phore to a streptavidin nanoparticle, the imaging re-
sults show high tumor accumulation and strong tu-
mor-to-normal tissue contrast by both fluorescence 
and nuclear imaging. The subsequent biodistribution 
study confirmed the specific tumor accumulation of 
radioactivity at 40 h was 21 ID%/g and therefore 
much higher than all other tissues including liver, 
heart, kidney, spleen, and muscle that accumulated 
8.7, 2.5, 6.9, 7.2, and 1.9 ID%/g, respectively [75]. In 
Cohen‟s work, IRDye800CW was coupled with mon-
oclonal antibodies of cetuximab and bevacizumab 
with 89Zr multi-labeling for optical imaging of tumor 
targets. The biodistribution studies showed that blood 
clearance was enhanced and live uptake was in-
creased at 24 to 72 hours post injection when 2 or 
more eq of dye had been coupled to mAbs. This study 
realized that after labeling with IRDye800CW, optical 
imaging can be used for accurate quantification of the 
biodistribution of mAbs (Figure 2) [76].  
 
 
Figure 3. Optical imaging with 89Zr-bevacizumab-IRDye800CW 
in a tumor-bearing mouse. Adapted from [76]. 
 
In the area of cancer diagnosis, organic dye and 
semiconductor nanocrystals (so called quantum dots 
(QDs) or quantum rods (QRs) attract attentions be-
cause of its unique optical properties to be fluorescent 
probes or luminescent nanoprobes for biological ap-
plications, ranging from immunoassays to live cell 
and tissue imaging, especially in cancer detection 
[77-82]. Such nanomaterials have their advantages 
over traditional fluorescent probes such as organic 
dyes and fluorescent proteins [79, 83]. For example, 
they have robust photochemical stability, high quan-
tum yield, and excellent resistance to chemical and 
photochemical degradation, as well as size-tunable 
photoluminescence that ranges from visible to near-IR 
with sharp spectral bands [84]. Also, QDs with dif-
ferent emission colors can be simultaneously excited 
with a single light source, with minimal spectral 
overlap, providing significant advantages for multi-
plexed detection of molecular targets [85, 86]. Thus, 
with conjugation with antibody and drug on the same 
QDs, this kind of theranostic reagent can be used as 
new type of probes for optical bioimaging and treat-
ment on cancer.  
Although there are significant advantages of 
semi-conductor nanocrystal QDs in the application of 
optical imaging for cancer detection, the potential 
toxicity cannot be ignored due to the existing of 
Cadmium element component inside the particles. In 
order to alleviate possible toxicity and increase the 
stability of QDs in biological field, Ding et al suc-
cessfully employed carboxyl functional Pluronics 
F127 (F127COOH) into the antibody conjugated QDs 
for pancreatic cancer detection and obtained satisfied 
results. They successfully applied anti-mesothelin 
antibody in vivo for pancreatic cancer detection [87]. 
The in vitro and in vivo toxicity study showed the low 
damage to cells and tissues in small animals. Another 
alternative on optical imaging is using biodegradable 
polymer encapsulated NIR dye for cancer detection 
[88]. With proper fluorescent dye or drug encapsula-
tion, this kind of biodegradable copolymer can be 
conjugated with target ligands or specific antibody for 
all purpose of tumor targeting. Because of the con-
cerning about the possible toxicity, researchers also 
generated a “pure” bioconjugated luminescent silicon 
quantum dots for cancer detection [89, 90]. This kind 
of luminescent probe can even used for sentinel 
lymph node mapping since it is one of the most im-
portant site that the metastatic happened [91]. Alt-
hough the above nanomaterials have their advantages 
over traditional fluorescent dye probes, batch to batch 
reproducibility and quantization of the labeled drug 
still need further investigation. Whether the biodis-
tribution of the labeled therapeutic antibodies is sig-
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nificantly affected by the nanomaterials remains a 
question to be addressed.  
Over the past years, different kinds of optical 
imaging techniques have been developed for bio-
medical applications, including various microscopy 
methods for in vitro and ex vivo applications as well 
as several methods for in vivo applications such as 
bioluminescence imaging, fluorescence imaging, ul-
trasound, dark field, diffused optical tomography, 
and optical coherence tomography, etc. Not only with 
help from expertise from studies on materials, various 
techniques can be used in combination, either simul-
taneously or sequentially, to provide complementary 
information from the same cells, tissues, organs, or 
animals [92-96]. Dr. Chen‟s lab applied fluorescent 
Maestro imaging system by real-time video imaging 
of protease expression in vivo, they found out that 
PEGylation of a molecular beacon with a specific size 
PEG can significantly alter the activation properties of 
the probe targeting matrix metalloproteinases 
(MMPs). And MMPs are a family of zinc-dependent 
endopeptidases and represent the most well-known 
proteases associated with tumorigenesis [97]. 
Among them, both fluorescence and biolumi-
nescence imaging techniques have been found wide 
applications for in vivo tumor optical imaging in 
mouse models and afford convenient, frequent visu-
alization and measurement of tumor biomarkers in a 
real time, sensitive, and noninvasive way. It also can 
allow for longitudinal detection of disease progres-
sion and therapeutic response in the same animals so 
as to minimize the subject-to-subject variability and 
reduce the animal number required by a traditional 
method. Importantly, such in vivo studies are very 
valuable for bridging the gap between in vitro and in 
vivo studies and facilitating preclinical and further 
translational studies [98].  
6. Images guided engineered nanoparti-
cles and antibodies cross blood-brain 
barrier (BBB) 
The blood-brain barrier (BBB) is a special tight 
capillaries membrane in CNS that formed from a con-
tinuous layer of endothelial cells bound together with 
tight junctions that allow very little transcellular or 
pericellular transport of molecules in blood fluid [99]. 
The BBB is an obstacle for clinicians and complicates 
the treatment of diseases of the central nervous sys-
tem (CNS). In order to develop BBB associated 
theranostic techniques, neuroimaging techniques 
have become increasingly important in assessing the 
biologic and physiologic properties of brain tumors 
and neurologic lesions (11). Although there are many 
successful imaging platforms including X-ray to-
mography (CT), optical imaging, positron emission 
tomography (PET), single-photon-emission computed 
tomography (SPECT), ultrasound (US), and magnetic 
resonance imaging (MRI), etc. MRI and combining 
with US seems the most successful applications in the 
clinic.  
Nanoparticles of course can be employed as ef-
fective tool for theranostic purpose. One biocompati-
ble stealth nanoparticles were designed by using mi-
croemulsion methodology to optimize BBB circum-
vention and encapsulate drugs for brain delivery. In 
vitro and in vivo data showed that the formulation 
has no effect on BBB barrier integrity and membrane 
permeability, or alteration of expression of the BBB 
tight-junction proteins, occludin, and claudin-1 while 
crossing BBB [100]. This kind of nanoparticles can be 
applied in theranostic through BBB. Nanoparticles 
encapsulation or conjugation of transporter substrates 
have already been used for enhance the access of 
drugs to the brain. In last decade, nano-sized carrier 
comprised by polymer, emulsion, liposome, nano-
crystals, micelles and etc, are already make great 
progress in pharmaceutical field for drug targeting 
and imaging. Dr. Ding and his colleagues applied 
inorganic gold nanords for siRNA delivery into brain 
has been succeeded in vitro and in vivo based on their 
contrast property in cancer detection [64, 101-103]. 
They also applied fluorescent nanocrystal as 
theranostic carrier for CNS drug delivery system 
[104]. Dr. Koffie et al prepared biodegradable 
nanocarrier systems made up of 
poly(n-butylcyanoacrylate) dextran polymers coated 
with polysorbate 80 (PBCA nanoparticles) to deliver 
BBB-impermeable molecular imaging probes into the 
brain for targeted molecular neuroimaging. They 
demonstrated that PBCA nanoparticles using as in 
vivo targeting of BBB-impermeable contrast agents 
can deliver BBB-impermeable targeted fluorophores 
of a wide range of sizes: from 0.5k-Da targeted polar 
molecules to 150k-Da tagged immune- globulins into 
the brain of living mice model of Alzheimer's disease. 
PBCA nanoparticles do not induce nonspecific BBB 
disruption, but collaborate with plasma apolipopro-
tein E to facilitate BBB crossing [105]. Dr. Qiao et al 
conjugated lactoferrin (Lf) with poly(ethylene glycol) 
(PEG)-coated Fe3O4 nanoparticle to cross BBB by re-
ceptor-mediated transcytosis via the Lf receptor pre-
sent on cerebral endothelial cells. The MRI images 
confirmed that in vivo experiments, Fe3O4-Lf probe 
exhibited an enhanced effective measure for deliver-
ing the nanoparticles across the BBB [106, 107].  
It is well-known that few of those antibodies can 
penetrate the shield of tightly packed cells known as 
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BBB. Normally, antibody concentrations in the brain 
are typically about a thousand times lower than in the 
blood. In the recent finding, Dr. Watts and his collab-
orators report the design of an antibody that sur-
mounts this obstacle. This antibody had the function 
of targeting two proteins. One is called β-secretase 1, 
which is a popular target for drugs to treat Alzhei-
mer's disease; the second protein targeted by the an-
tibody is the transferrin receptor, which activates a 
molecular channel that normally imports iron into the 
brain. By clinging to this receptor, the antibody is 
transported into the brain, where it can act against 
β-secretase 1. The double-duty antibody performed 
well in mouse models of Alzheimer's disease: a day 
after receiving a single injection of the antibody, con-
centrations of amyloid-β in the brain plummeted by 
47% [108, 109]. 
Lee et al applied peptidomimetic monoclonal 
antibodies that target peptide transcytosis systems for 
the BBB in vivo. Murine monoclonal antibodies to the 
rat transferrin receptor, such as the OX26 monoclonal 
antibody, are targeted through the BBB on the trans-
ferrin receptor in the rat. The capillary depletion 
technique demonstrated transcytosis of the RI7-217 
rat monoclonal antibodies antibody can through the 
mouse BBB in vivo. The studies indicate rat mono-
clonal antibodies to the mouse transferrin receptor 
may be used for brain drug-targeting studies [110]. 
Dr. Boado and his colleagues used engineered murine 
monoclonal antibody to the human insulin receptor 
(HIR) as a brain drug delivery system for transport 
across the human BBB (Figure 4). The HIRMAb was 
humanized by complementarity determining region 
(CDR) grafting on the framework regions (FR) of the 
human B43 IgG heavy chain and the human REI 
kappa light chain. The humanized HIRMAb avidly 
bound to the HIR of isolated human brain capillaries, 
which are used as an in vitro model system of the 
human BBB. The humanized HIRMAb was radio-
labeled with 125-iodine, and injected intravenously 
into an adult, anesthetized Rhesus monkey. Brain 
scanning showed the humanized HIRMAb was rap-
idly transported into all parts of the primate brain 
after intravenous administration. The humanized 
HIRMAb may be used as a brain drug and gene de-
livery system for the targeting of large molecule 
therapeutics across the BBB in humans [111]. 
 
 
Figure 4. Film autoradiography of Rhesus monkey brain removed 
2 h after an intravenous administration of [125I]-humanized 
HIRMAb. Coronal sections through the forebrain (top panel), 
midbrain (middle panel), and hindbrain/cerebellum (bottom panel) 
are shown. Adapted from [111]. 
7. Conclusions and Perspectives 
Molecular imaging takes advantage of the tradi-
tional diagnostic imaging techniques and introduces 
molecular imaging probes to measure the expression 
of indicative molecular markers at different stages of 
diseases. It has been widely reported the importance 
and advantages of various imaging modelities in the 
drug development. We summarized the distribution 
and pharmacokinetics studies using MR imaging, CT, 
PET imaging, SPECT imaging, optical imaging as well 
as SPECT etc. Among those imaging modalities, PET, 
SPECT and MRI imaging has been used in clinical 
study, while optical imaging is still on the way of get-
ting through; almost all of the studies using optical 
imaging are in the preclinical status. Non-invasive 
detection of various molecular markers of diseases 
can allow for much earlier diagnosis, earlier treat-
ment, and better prognosis that will eventually lead to 
personalized medicine. For using molecular imaging 
to investigate the biodistribution and PK properties of 
theranostics, the following aspects still need further 
investigation: 
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 Major advantages of radionuclide-based molec-
ular imaging techniques (SPECT and PET) over 
other modalities (optical and MRI) are high sen-
sitivity (picomolar level), quantitation, and 
non-tissue penetration limitation. However, one 
disadvantage is that the resolution of either 
SPECT or PET is not as high as MRI. In most 
cases, the modalities such as PET or SPECT can 
be applied for studies of biodistribution, PK 
study properties, and/or tumor-targeting effi-
cacy in non-invasive image ways. 
 Comparing with other medical imaging tech-
niques such as CT, MRI provides good contrast 
between the different soft tissues of the body, 
which make it especially useful in imaging brain, 
muscles, the heart, and cancers. CT is preferable 
in the application of bones imaging while MRI is 
good for tissue imaging. 
 For both PET imaging and optical imaging, the 
image only showed the signals from the radioi-
sotope probe or fluorophore probe, while the 
probe may still attach to the metabolite of drug 
even after the degradation of the drug. Therefore, 
the imaging method is not able to distinguish the 
metabolite or parent drug. Using sodium do-
decyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) or size exclusion HPLC for con-
firming the stability of the labeled antibody 
therapeutics may be a good way of providing 
more information of metabolism. For labeled 
antibody, due to its therapeutic effect and detec-
tive property, the labeled antibody can also be 
considered as theranostics if it is used in the field 
of treatment and diagnosis. 
 After obtaining biodistribution data using mo-
lecular imaging in preclinical study, establishing 
physiologically based pharmacokinetic model 
(PBPK) and allometric scaling for translation of 
animal data to human clinical pharmacology is 
very important. Further research effort is needed 
on establishing PBPK model using imaging data. 
 For the later clinical application, the absorption, 
distribution, metabolism/degradation and ex-
cretion of theranostics need to be extensively 
studied. Various imaging modalities mentioned 
in this review are useful quantitative tools for 
investigating the above biopharmaceutical 
properties of theranostis. 
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